Gyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading Volume – What’s Next?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares saw strong trading volume on Thursday . 28,842 shares traded hands during trading, a decline of 61% from the previous session’s volume of 74,771 shares.The stock last traded at $12.35 and had previously closed at $11.90.

Gyre Therapeutics Price Performance

The firm has a 50-day moving average of $12.76 and a two-hundred day moving average of $12.62.

Hedge Funds Weigh In On Gyre Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of GYRE. Geode Capital Management LLC raised its holdings in Gyre Therapeutics by 16.9% in the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after buying an additional 43,840 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after acquiring an additional 90,557 shares during the period. State Street Corp boosted its position in Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares during the period. Advantage Alpha Capital Partners LP acquired a new stake in Gyre Therapeutics in the 3rd quarter valued at $334,000. Finally, WINTON GROUP Ltd purchased a new position in Gyre Therapeutics in the second quarter valued at about $220,000. 23.99% of the stock is owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.